IPCA to sell Ankleshwar drug ingredients unit for Rs 22.15 crore

Core Business DivestedStrategic Transactions View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1287.50

prior close

₹1291.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.7%-1.8% vs market

Pharmaceuticals peers, median of 153sector+0.3%-1.4% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Midcap 150 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.1

15m

-1.0

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.7-1.8+0.3-1.4

Next day

-0.2+0.9-1.1+0.9-1.2

-0.7+0.7-1.5+0.6-1.4

-1.2+0.5-1.7+0.3-1.5

+0.7+1.3-0.6+0.3+0.4

+0.3+1.3-1.0+0.1+0.2

-0.2+1.7-1.9+0.7-0.9

15d

+3.3+2.8+0.5-1.0+4.3

+11.0+2.9+8.1-2.1+13.0

+11.2+2.5+8.7-4.2+15.4

+14.9-2.1+16.9-12.1+26.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IPCA Laboratories plans to sell its Ankleshwar drug intermediates and bulk drugs manufacturing unit to Suleshvari Pharma on a slump sale basis for Rs 22.15 crore. The unit earned Rs 50.24 crore in the year ended March 2025, or 0.74% of company income, and had a written-down asset value of Rs 15.80 crore. Completion is targeted by December 31, 2025, subject to approvals. The sale aims to cut costs and will not change shareholding.

Likely market impact

The sale may lower operating costs and simplify operations, while IPCA says it will have no material effect on its business or financials.